Fourteen patients received 5-iodo-2'-deoxyuridine (IdUrd) before PHARmAcor, THER 1988;44:369-75.) 
Because it is ethically difficult to justify performing surgical procedures primarily for purposes of research, an alternative approach is to structure research around surgical interventions that are already planned and justified for other purposes. Biopsy samples obtained at the time of scheduled surgery can be used for research purposes. These examinations can be made much more enlightening if the patient has received some type of antitumor treatment before surgery. A clear demonstration of the safety of any presurgical treatment is required, especially in light of any interference with the scheduled surgery, coagulation, or the wound healing process.
We have undertaken a clinical evaluation of the use of intrahepatic arterial infusion of 5-iodo-2'-deoxyuridine (IdUrd) in patients with hepatic metastases from colorectal carcinoma.' All patients required laparotomy for placement of a semipermanent catheter in the hepatic artery. This surgical requirement provided a unique opportunity to obtain biopsy specimens of the target tumor and surrounding normal tissue. To maximize the information obtained from these specimens, 369 370 Speth et al. all patients received a 3-day infusion of IdUrd before surgery. The effect of various maneuvers that might enhance selectivity (changes in dose rate, route of delivery, biochemical modulation) could be readily examined with this model system.
IdUrd is a competitive analog of thymidine (dThd). Its cytotoxic activity and radiosensitizing properties have been demonstrated both in vitro' and in vivo.'" IdUrd was chosen for our study because this drug has never been adequately evaluated in clinical trials and because its high total body clearance' was a favorable property for intraarterial use.' Its mechanism of action is thought to be related to incorporation into deoxyribonucleic acid (DNA), which is readily measurable in tissue samples.'" Hepatic metastases were considered to be an ideal setting, because a dThd analog could maximally exploit differences between dividing tumor cells and nondividing liver cells.
In this study, incorporation of IdUrd into the DNA of normal hepatic tissue and tumor tissue was used as an index of drug selectivity. DNA levels were determined by enzymatic degradation and HPLC measurement of nucleosides. The fraction of tumor cells that divided during the 3-day infusion was determined by flow cytometric analysis. A comparative pharmacokinetic study of intravenous vs. intraarterial delivery of IdUrd is presented, as well as the impact of 5-fluoro-2'-deoxyuridine (FdUrd) on IdUrd incorporation into DNA. Furthermore, we estimated the hepatic extraction for IdUrd and measured the patterns of two key enzymes (thymidylate synthetase and thymidine kinase) in normal and tumor tissue.
MATERIAL AND METHODS
Clinical. Patients with histologically confirmed, unresectable tumors located in the liver (metastases from primary colorectal carcinoma) were eligible for study. All patients gave informed consent to participate and the study was approved by the Institutional Clinical Research Committee.
IdUrd (NSC 39661) for infusion was supplied by the National Cancer Institute. FdUrd was obtained from commercial suppliers. When coadministered, the two drugs were mixed together and infused simultaneously. Patients were admitted before surgery and an IMED Corp. infusion pump (San Diego, Calif.) was used to deliver a 3-day continuous infusion of IdUrd or FdUrd plus IdUrd. The drug solution was infused through either a peripheral vein or a flexible silicone rubber catheter that had been originally placed into the hepatic artery for purposes of percutaneous diagnostic angiography.
CLIN PHARMACOL THER OCTOBER 1988 The infusion rates (in milligrams per square meter per day) for IdUrd or IdUrd plus FdUrd were approximately the maximally tolerated values for a 14-day infusion period, based on our experience." Because the infusion period for this study was limited to 3 days, it was expected that there would be no toxicity produced at these dosages.
At the time of laparotomy for placement of the semipermanent catheter in the hepatic artery, biopsy specimens of tumor and normal tissue were taken for pharmacologic studies. Two weeks after surgery, patients began the intraarterial therapeutic portion of the study. The clinical results (toxicity and response) of the treatment portion of this study will be reported separately. ' Enzyme studies. 
RESULTS
Fourteen patients entered this study; 12 were male and 2 were female. Median age was 58 years (range 44 to 68 years). Performance status was 70% to 100% (Karnofsky). There was no toxicity observed subsequent to any infusion in this study.
For five patients who received a 3-day infusion of intravenous IdUrd (1000 mg/ m2/ day) before surgery, the incorporation of IdUrd into tumor DNA averaged 3.1%, with a range from 1.7% to 4.5% (Table I, When the same dose of IdUrd (1000 mg/ m2/ day for 3 days) was delivered via a percutaneous catheter placed in the common hepatic artery (Table I , patients F and G), incorporation of IdUrd into tumor DNA was up to twofold greater than for the intravenous route. In patient H, the infusion catheter was selectively placed in the right branch of the hepatic artery and tumor DNA levels in the right lobe were 10.5%, whereas tumor DNA levels in the left lobe were only 1.6% (Table  I) . In this case, delivery of IdUrd to the left lobe required an initial passage of drug through the right lobe, followed by recirculation to the left lobe via systemic circulation. It is noteworthy that the tumor DNA level in the left lobe was lower than any values measured after intravenous drug delivery (Table I , patients A to E). This observation is consistent with presystemic elimination of IdUrd during its initial transit through the right lobe (first-pass effect). The overall selectivity of regional drug delivery in this case was 10.5% vs. 1.6%, or about sevenfold greater. For two of three patients who received intraarterial IdUrd, DNA levels in normal liver were For the third patient, a value of 2.4% was determined for substitution in DNA of normal liver (Table I) .
In one case, the intravenous IdUrd infusion rate was 400 rather than 1000 mg/m2/day for the 3-day infusion period (Table II, (Table III) .
For the 3-day intravenous infusion data, if one third of the tumor cells are labeled and the average dThd substitution is 3.1% (Tables I and II) , then 10% is the average substitution for those tumor cells that contain IdUrd ( Fig. 1) arterial catheterization (Table I , patient H), overall tumor substitution was 10.5%, so the average substitution in those tumor cells that actually contain IdUrd would be 32%.
Enzyme activities for TK and TS (Table IV) were measured on the same samples used for DNA analysis. TK activity in tumor samples tended to be higher than in normal liver samples, but the differences were not dramatic. TS activity in tumors was more impressively elevated, 10-to 35-fold higher than in normal liver. The presurgical infusion of IdUrd could have inhibited both enzymes. The dose rate and period of infusion were all standardized for the four patients listed in Table   IV . However, the length of time between the end of infusion and sample acquisition could not be carefully controlled and ranged from 2 to 6 hours.
Hepatic extraction of IdUrd can be calculated from the steady-state plasma levels for six patients who received separate intraarterial and intravenous infusions. The intravenous infusion rate was slightly lower than the intraarterial infusion rate (1000 vs. 1333 mg / m2/ day), so a correction was made for this difference. As shown in Table V , the corrected extraction values ranged from 29% to 72% (median 70%).
DISCUSSION
The results from this pharmacologic study indicate that IdUrd possesses several characteristics that would be expected to promote selective killing or radiosensitization of tumor cells. First, for intravenous delivery it was shown that tumor cells preferentially incorporate IdUrd compared with normal liver cells. Second, when the intraarterial route was used, there was additional selectivity for target cells. Tumor incorporation of IdUrd was higher, and first-pass hepatic extraction lowered systemic tissue exposure. Third, biochemical modulation with FdUrd or other drugs may provide some increased incorporation of IdUrd into tumor DNA. However, interpatient variability indicates that the particular combination used in this study was not practical. In fact, for some patients, the combination of FdUrd + IdUrd produced lower levels of IdUrd in tumor DNA than was achieved with single-agent IdUrd.
Even a hint of tumor selectivity may be worth pursuing, because our previous study of DNA from normal granulocytes showed that FdUrd did not alter IdUrd levels."
Flow cytometric analysis provided additional insight regarding both tumor cell kinetics and interpretation of HPLC results. Substantially more tumor cells than liver cells were labeled with IdUrd during the 3-day infusion period. In general, this result was expected, based on our rationale for selectively treating the cell population that was turning over more rapidly. However, the median value of 32% labeled tumor cells was perhaps higher than anticipated. This fraction corresponds to a potential tumor doubling time of 10 days. Because the net growth of these tumors is considerably slower, it would appear that substantial tumor cell death and subsequent necrosis is occurring.'
The optimal time for tumor exposure to drugs, es- pecially cell cyclespecific agents, is closely related to their potential doubling time. Based on this rapid turnover time for metastatic tumors in the liver, treatment protocols that provide 14-day drug exposure''''"8 would be favored over 1-to 5-day infusion periods.
Due to the difficulties of using flow cytometric analysis to quantitate IdUrd incorporation into DNA' (Speth et al., unpublished data) , only qualitative data were obtained by these methods. In addition to considerations regarding optimal exposure time, there is also a need to define the most appropriate infusion rate or exposure concentration. In general, the highest tolerable infusion rate is desirable, but a lower infusion rate for a longer period of time may have some advantages. The utility of increasing the infusion period may be limited by saturation of drug activation processes. The most direct approach would be to examine incorporation into DNA vs. the infusion rate. The present study did not have adequate numbers of patients to pursue this parameter, but does demonstrate the feasibility of such an approach.
Our prior attempts at pharmacologic studies with tumor biopsy specimens obtained through serendipitous events have never been satisfactory. The results of this study demonstrate that it is possible to organize the process of tissue acquisition to maximize pharmacologic knowledge. In addition to pharmacologic end points, it should be possible to determine some rela- 
